Their population-based case-control study involving 1,269 hospitalized cases of acute pancreatitis demonstrated that patients who were exposed to GLP-1 RAs within the last 30 days were over twice as likely to develop pancreatitis (adjusted OR: 2.24), while exposed within the past one to 24 months had a twofold increased risk (adjusted OR: 2.01) compared to non-users. The gene discussed is GLP1R; the disease is acute pancreatitis.